StarMab BioMed Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 7

StarMab BioMed General Information

Description

Researcher and developer of innovative biopharmaceutical medicines designed for different diseases. The company is dedicated to the discovery and development of innovative drugs, as well as clinical R&D and commercialization worldwide, focusing on the fields of tumor, inflammatory diseases, and ophthalmology treatment, providing patients with reliable and efficient products.

Contact Information

Website
www.starmab.com.cn/gywm
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bohui Innovation Building, Life Science Park
  • Changping District
  • Beijing, 102206
  • China
+86 135
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Bohui Innovation Building, Life Science Park
  • Changping District
  • Beijing, 102206
  • China
+86 135

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StarMab BioMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A1) 07-Dec-2023 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2021 Completed Pre-Clinical Trials
1. Early Stage VC 09-Sep-2019 Completed Pre-Clinical Trials
To view StarMab BioMed’s complete valuation and funding history, request access »

StarMab BioMed Patents

  • 17

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

StarMab BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4805036-A1 Monospecific and multi-specific antibodies Pending 06-Nov-2023
WO-2025101525-A1 Monospecific and multi-specific antibodies Inactive 06-Nov-2023
EP-4805397-A1 Multi-specific cancer-targeting antibodies Pending 06-Nov-2023
WO-2025101526-A1 Multi-specific cancer-targeting antibodies Inactive 06-Nov-2023
EP-4547270-A2 Monospecific and multi-specific antibodies Pending 28-Jun-2022 C07K16/2878
To view StarMab BioMed’s complete patent history, request access »

StarMab BioMed Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Guangda Huitong Private Equity Fund Management Growth/Expansion Minority
Zhuhai Hi-Tech Financial Venture Capital Management Venture Capital Minority
Zhuhai Technology Venture Capital Venture Capital Minority
Chang'an Capital Venture Capital Minority
CICC Capital PE/Buyout Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

StarMab BioMed FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process